Human Cortical Neurons (iPSC-derived, Normal)

Product Overview

The human cerebral cortex is composed of a mix of cell types including long-range excitatory projection (or pyramidal) neurons and local inhibitory neurons. During embryonic development, excitatory and inhibitory cortical neurons originate separately outside of the cerebral cortex in the ventricular zone and subventricular zone (VZ and SVZ) and the ganglionic eminences, respectively, and migrate into the cortex in a layer specific manner ^{(1, 2)}. Cortical neurons participate in a range of higher order brain functions such as processing and integration of sensory and motor information and regulate complex behaviors. Dysfunction of cortical neuron circuits is central to the pathophysiology of many neurodevelopmental and neurodegenerative disorders ^{(3, 4, 5, 6, 7)}, making these cells a useful model system for disease research ^{(8, 9)}. Furthermore, cortical neurons can be co-cultured with other cell types to recapitulate disease phenotypes ^{(5, 10)}.

iXCells Biotechnologies is proud to offer a fully differentiated, pure, and functional human iPSC-derived cortical neuron product that displays typical neuronal morphology and expresses the key forebrain and synaptic markers typical of this cell type(Figure 1) when cultured in the Cortical Neuron Maintenance Medium (Cat# MD-0093). In addition, our iPSC-derived cortical neurons can be co-cultured with microglia or glial cells for drug screening applications.

Figure 1. iPSC-cortical neurons were recovered and cultured at a density of 100,000 cells per well on Cultrex-coated 48-well culture plates for 3 days. Cells were stained with TBR1 (Red) and TUJ1 (Green). DAPI nuclei counter stain is shown in blue. Scale bar: 100 um.

Product Details

Product Information

References

(1) Lui JH, Hansen DV, Kriegstein AR. (2011). “Development and evolution of the human neocortex.” Cell. 146(1):18-36. 

(2) Batista-Brito R, Fishell G. (2009). “The developmental integration of cortical interneurons into a functional network.” Curr Top Dev Biol. 87:81-118.

(3) Vitrac A, Cloëz-Tayarani I. (2018). “Induced pluripotent stem cells as a tool to study brain circuits in autism-related disorders.” Stem Cell Res Ther. 9(1):226.

(4) Donegan JJ, Lodge DJ. (2020). “Stem cells for improving the treatment of neurodevelopmental disorders.” Stem Cells Dev. 29(17):1118-1130.

(5) Penney J, Ralvenius WT, Tsai Li-Huei. (2020). “Modeling Alzheimer's disease with iPSC-derived brain cells.” Mol Psychiatry. 25(1):148-167.

(6) Kühn R, Mahajan A, Canoll P, Hargus G. (2021). “Human induced pluripotent stem cell models of frontotemporal dementia with Tau pathology.” Front Cell Dev Biol. 9:766773.

(7) Weng OY, Li Y, Wang L. (2022). “Modeling epilepsy using human induced pluripotent stem cells-derived neuronal cultures carrying mutations in ion channels and the mechanistic target of rapamycin pathway.” Front Mol Neurosci. 15:810081.

(8) Dolmetsch R, Geschwind DH. (2011) “The human brain in a dish: the promise of iPSC-derived neurons”. Cell. 145(6):831-834.

(9) Silva CM, Haggarty SJ. (2020) “Human pluripotent stem cell-derived models and drug screening in CNS precision medicine”. Ann N Y Acad Sci. 1471(1):18-56.

(10) Pintacuda G, Martin JM, Eggan KC. (2021) “Mind the translational gap: using iPS cell models to bridge from genetic discoveries to perturbed pathways and therapeutic targets.” Mol Autism. 12(1):10.